The reduction of viability by DAC treatment was more pronounced in GDM-1 as compared to other AML cell lines (HL-60, MOLM-13, OCI-AML-3) which do not express MNX1 (Supplementary Fig. 1C), indicating a lower sensitivity of these lines to DAC and suggesting a positive effect of MNX1 on AML cell viability in GDM-1. This evidence concerns the gene MNX1 and acute myeloid leukemia.